NeoMatrix Therapeutics (NMT) Peptide Discovery Advances Treatment of Burn Injury. Novel Peptide Shows Promise for the Treatment of Severe Burns in Phase 1 clinical trial
STONY BROOK, NY, February 5, 2025 (EINPresswire.com) -- Neomatrix Therapeutics, Inc. has announced positive topline data from the conclusion of its Phase 1 clinical trial for cNP8, a small peptide derived from the naturally occurring protein fibronectin. The cNP8 Phase 1 First in Human, Single Ascending Dose study was conducted in 32 healthy participants and was designed to examine the safety, tolerability, and pharmacokinetics. cNP8 was generally well-tolerated in healthy participants receiving single doses up to 0.03mg/kg. No serious adverse events were reported, and all participants completed the study.
NeoMatrix Therapeutics’ cNP8 has been shown to play an important role in many biological processes, including wound healing. In preclinical studies using a validated animal model, cNP8 demonstrated the ability to limit burn injury progression, the cascade of events by which the tissue damage from the initial burn spreads into the deeper layers of the skin. The extent of progression after the initial burn determines the need for surgery and the extent of consequential scarring and disfigurement from serious burns. cNP8’s optimum time of delivery is 8 to 24 hours.
“We see significant potential for NeoMatrix Therapeutics to continue to lead these programs through clinical investigations and identify new opportunities for the advancement of burn and other potential therapies” says Richard A. Clark, MD, company president and Chief Scientific Officer.
The U.S. Army Medical Research Acquisition Activity, 808 Schreider Street, Fort Detrick MD 21702-5014, is the awarding and administering acquisition office.This work was supported by the Assistant Secretary of Defense for Health Affairs, in the amount of $2,199,979, through the Defense Medical Research and Development Program under Award No. HT94252311064. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs.”
Safe Harbor:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995 and are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties, many of which are outside of our control.
There can be no guarantees that our pipeline products will receive the necessary regulatory approvals or be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. These risks and uncertainties include, among others, our limited operating history, limited cash and a history of losses; our ability to obtain adequate financing to fund our operations; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure required U.S. Food and Drug Administration or other approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including on our operations and clinical trials; our ability to meet anticipated clinical trial commencement and completion dates and regulatory submission dates; negative or inconclusive results from our clinical trials or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; and delays; and changes in regulatory requirements, policy and guidelines. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
Richard A. Clark, M.D., President & Chief Scientific Officer: raclark@neomatrixtx.com.
留言